2/12/2014 8:12:49 AM
Actelion Ltd. (ATLN)’s Opsumit may face a clinical trial comparing its effectiveness with Gilead Sciences Inc. (GILD)’s lung drug Letairis, potentially threatening the treatment’s predicted dominance. A so-called head-to-head study is “something we have to consider that might be an important next study for us,” Gilead Chief Operating Officer John Milligan said yesterday in an interview at Bloomberg News in New York. He said the Foster City, California-based company has no concrete plans yet for such a trial. Actelion shares fell as much as 3.1 percent.
Help employers find you! Check out all the jobs and post your resume.
comments powered by